ValuEngine upgraded shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) from a strong sell rating to a sell rating in a research note released on Tuesday.

Marinus Pharmaceuticals (NASDAQ MRNS) traded down 2.04% on Tuesday, reaching $1.92. 167,666 shares of the company traded hands. The company has a 50-day moving average price of $1.47 and a 200-day moving average price of $1.39. The company’s market capitalization is $43.04 million. Marinus Pharmaceuticals has a 12 month low of $0.82 and a 12 month high of $2.73.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Monday, May 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. Equities research analysts expect that Marinus Pharmaceuticals will post ($1.00) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/marinus-pharmaceuticals-inc-mrns-rating-increased-to-sell-at-valuengine/1461620.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. KCG Holdings Inc. raised its position in Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 14,692 shares during the last quarter. Jennison Associates LLC purchased a new position in Marinus Pharmaceuticals during the first quarter worth about $690,000. Granite Point Capital Management L.P. purchased a new position in Marinus Pharmaceuticals during the first quarter worth about $1,372,000. Finally, Nexthera Capital LP purchased a new position in Marinus Pharmaceuticals during the first quarter worth about $1,416,000. 32.69% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.